Imperial College London

ProfessorPhilippeSteg

Faculty of MedicineNational Heart & Lung Institute

Visiting Professor
 
 
 
//

Contact

 

p.steg

 
 
//

Location

 

c/o Prof Kim FoxGuy Scadding BuildingRoyal Brompton Campus

//

Summary

 

Summary

Dr Steg has been a Professor of Cardiology at Université Paris - Diderot since 1994. He is also Professor at the National Heart and Lung Institute, Imperial College, London, UK. He works as an interventional cardiologist and is Director of the Coronary Care Unit of Hôpital Bichat, in Paris, France. He is also Director of the “Clinical Research in Atherothrombosis” Research Team, which belongs to INSERM U-1148, Paris and a co-coordinator of the Département Hospitalo-Universitaire FIRE (Fibrosis, Inflammation and REmodeling) affiliated with INSERM, Université Paris-Diderot and Assistance Publique – Hôpitaux de Paris. He is chair of the FACT (French Alliance for Cardiovascular clinical Trials) academic research network.

Dr Steg’s research interests are in the field of coronary artery disease. He is a former member of the Board of the French Society of Cardiology, an honorary member of the Institut Universitaire de France, and received the silver medal of the European Society of Cardiology in 2011.

Dr Steg led the TAO and EUROMAX trials and is currently chairing or co-chairing several trials or registries, such as ODYSSEY-CV Outcomes, CLARIFY, THEMIS. Dr Steg has authored more than 650 articles in peer-reviewed international journals. He is a member of the editorial boards for Circulation, Circulation: Cardiovascular Interventions, the European Heart Journal, and the European Heart Journal – Cardiovascular Pharmacotherapy. He is deputy editor for the Journal of the American College of Cardiology. Finally, Dr Steg was co-chair of the task force in charge of the 2012 ESC Guidelines for management of ST-segment elevation myocardial infarction.

E-mail: gabriel.steg@bch.aph.fr

Publications

Journals

Eccleston DS, Kim JM, ten Berg JM, et al., 2021, The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after PCI in patients with atrial fibrillation (a RE-DUAL PCI subgroup analysis and comparison to other dual antithrombotic therapy trials), Clinical Cardiology, ISSN:0160-9289

Puymirat E, Cayla G, Simon T, et al., 2021, Multivessel PCI Guided by FFR or Angiography for Myocardial Infarction, New England Journal of Medicine, ISSN:0028-4793

Bhatt DL, Kaski JC, Delaney S, et al., 2021, Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous intervention., Int J Cardiol

Schwartz GG, Gabriel Steg P, Bhatt DL, et al., 2021, Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial, Circulation, Vol:143, ISSN:0009-7322, Pages:1109-1122

Magnani G, Ardissino D, Im K, et al., 2021, Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction, Journal of the American Heart Association, Vol:10, ISSN:2047-9980

More Publications